Washington People: Chakravarthi Narasimhan

It’s not easy being a Chicago Cubs fan. Just ask Chakravarthi Narasimhan, PhD, the Philip L. Siteman Professor of Marketing at Olin Business School. Though Narasimhan’s sports life may have more downs than ups, his professional life has been a grand slam. “Chak is a key member of the school’s senior faculty and has built an outstanding marketing group here at Olin,” says colleague Todd Milbourn, PhD.

Making R&D more cost effective

In dating — as in business — you don’t want to be looking for a date when you’re desperate; you want to find one before you become desperate. Business professors at Washington University in St. Louis have found that how firms manage their research and development (R&D) pipelines could mean the difference between always having products in the works and searching desperately for new goods. More…

Pharmaceutical industry wastes $50 billion a year due to inefficient manufacturing

The pharmaceutical industry could be wasting more than $50 billion a year in manufacturing costs alone, costs that could translate in to lower prices or greater research and development – according to findings of the largest empirical study ever performed of pharmaceutical manufacturing and the Food and Drug Administration monitoring policies. More…

Health Care Policy Experts

Washington University School of Medicine in St. Louis is a long-time leader in medical research and clinical practice. The school employs a number of experts in many areas of expertise, including health care policy issues. Under the direction of former dean William Peck, the university has established the Center for Health Policy to: Identify key […]

Business schools collaborate with FDA on drug manufacturing performance study

The U.S. Food and Drug Administration will collaborate with Assistant Professor Jeffrey T. Macher of the Robert Emmett McDonough School of Business at Georgetown University and Associate Professor Jackson A. Nickerson of the Olin School of Business at Washington University in St. Louis as part of its strategic initiative to modernize the regulation of pharmaceutical manufacturing and product quality. Under the terms of the material transfer agreement with the FDA, Macher and Nickerson will conduct research and analysis to help the FDA identify the factors that predict manufacturing performance to further refine the agency’s risk-based site selection model for inspections as well as its other efforts to target identified risks to pharmaceutical quality and strengthen its pharmaceutical compliance program.